Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 31, 2023
July 27, 2023
4fbb7da7-e7da-4ffb-a835-53f0fa1a9dda
Related Documents
Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry
Guidance DocumentAugust 5, 2020Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022
Guidance DocumentMay 1, 2023Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry
Guidance DocumentNovember 9, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.